SPOTLIGHT -
Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL
Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.
Read More
Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL
Anita Kumar, MD, discusses treatment options for patients with mantle cell lymphoma who progress on BTK inhibitors.
Dr. Kumar on the Future Directions With Pirtobrutinib in MCL
Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.
Dr. Kumar on Addressing Unmet Needs in Mantle Cell Lymphoma
Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.
Dr. Kumar on Navigating CAR T-Cell Therapy–Related Toxicities in MCL
Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.
Dr. Kumar on the Clinical Implications of the AIM Study in Mantle Cell Lymphoma
Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma.
Dr. Kumar on Patient Considerations for Treatment in Relapsed/Refractory MCL
Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
